Biosimilars Congregation 2012
24th February - 24th February 2012 | UK
Category: R&D
Address: Thistle Marble Arch Hotel, London, UK
Organiser: Virtue Insight
Website: CLICK HERE to open.Key Themes Discussed:
• Reviewing some of the challenges in clinical study design for biosimilar development arising from endpoint variability, changes in clinical practice, and evolution in understanding of the biology of the disease
• How should the pharma and generics industries approach the rapidly emerging and developing biosimilar market? The future of next generation Biosimilars
• How are policy makers shaping the contours of this new generic frontier, and what implications they have for current biologic drug development and patent protection?
• Identifying issues and solutions surrounding biosimiliars and clinical trials.
• Next generation monoclonal antibody development and clinical challenges with biosimilar drug development
• Overcoming pricing and reimbursement challenges to maximise the ROI
• Determining the right investments & potential returns from Biosimilars
• Commercial challenges and opportunities - strategies to develop Biosimilars
• Biosimilars Vs Bio-betters – positioning for a new market with lucrative prospects
• Learn to implement best practices through recent successful strategies and business models – real time case studies
• Analyze the FDA's current view of biosimilars
• The developing regulatory framework in advanced and developing markets
• EMA Regulatory Opinions on Treatment of mAbs
• Critical issues in demonstrating biosimilarity and maintaining diligent quality control
• Be part of a major networking opportunity